INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 143 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $2,979,000 | -64.9% | 56,915 | -75.0% | 0.17% | -65.3% |
| Q3 2021 | $8,478,000 | -33.7% | 227,419 | -27.4% | 0.50% | -31.9% |
| Q2 2021 | $12,783,000 | -42.5% | 313,159 | -52.2% | 0.74% | -44.8% |
| Q1 2021 | $22,224,000 | -17.6% | 655,001 | -22.8% | 1.34% | -16.8% |
| Q4 2020 | $26,972,000 | +108.7% | 848,162 | +68.4% | 1.61% | +67.6% |
| Q3 2020 | $12,921,000 | +108.1% | 503,555 | +108.2% | 0.96% | +145.0% |
| Q2 2020 | $6,209,000 | +676.1% | 241,908 | +365.2% | 0.39% | +428.4% |
| Q1 2020 | $800,000 | -51.1% | 52,005 | -58.7% | 0.07% | -50.7% |
| Q2 2019 | $1,635,000 | – | 125,955 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |